You are here

Accipio Detects Brain Bleeds, Receives FDA 510(k) Clearance

AI Software Helps Physicians Prioritize Patients with Hemorrhagic Stroke or Intracranial Trauma

MaxQ AI (formerly MedyMatch, Tel Aviv, Israel) has received FDA 510(k) marketing clearance for Accipio, an artificial intelligence software that can rapidly detect brain bleeds in computerized tomography (CT) scans.

The software medical device is designed to be acutely sensitive to the presence of intracranial bleeding in the scans, and alerts the treating physician when bleeding is detected. The tool could help relieve physicians and emergency health care providers from high caseloads, rendering speedy diagnoses for patients in greatest need.

Accipio’s ability to detect suspected brain bleeds so speedily is ground-breaking. The potential impact is huge: saving just one patient from acute stroke in the 13,000 hospitals in the U.S. and Europe would bring about some $2 billion in savings in one year.

There are plans to also use the software in mobile stroke units. This would enable staff to differentiate between ischemic and hemorrhagic strokes and administer clot-dissolving drugs to the patient while en route to the hospital.

Sources: Mobihealthnews, November 12, 2018.

Recent Headlines

Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable